Creo Medical Share Discussion Threads

[imjustdandy] 18/9/2024 11:34

So the transaction today is 75% of current market cap. This has a very long way to run and the commercial alliance too is stunning.

[bladderman] 18/9/2024 11:34

This is overvalued now Take profits time

[peterrr3] 18/9/2024 11:29

Hi pacsltd, I guess seeing the potential for global commercialisation ahead of a buy-in counts for something, depending when you bought in of course. I've been watching this gain traction and topping up the dips, so you will have to excuse the enthusiasm.

[imjustdandy] 18/9/2024 11:28

Can we get back to 2 quid on the back of that alliance? What a transaction

[74tom] 18/9/2024 11:28

That's a really impressive deal, well done to all at Creo. They only paid €24.5m for Ablyn in 2020, so to sell 51% at a valuation of €72m 4 years later makes complete commercial sense. Could well catch some short sellers on the hop...

[zen12] 18/9/2024 11:27

Absolutely superb and £36.7 for 51%...so they still retain 49%

[dr biotech] 18/9/2024 11:26

Well that should remove any lingering doubts about funding. At the AGM Craig said that the distribution arm was valued at around 70m so I guess this is validation of that.

A key line here Creo and Micro-Tech have agreed to explore a co-branding and registration strategy for certain Creo core products into the large Chinese market.

One of the other things mentioned was that Intuitive (and CMR) have struggled to place their units into China as they come up against a lot of home grown competition which has the backing of the govt. Hopefully having this alternative channel in will help. As always it will take a while, but I see this a decent step forwards.

[someuwin] 18/9/2024 11:25

Great news - no more funding worries.

[imjustdandy] 18/9/2024 11:23

what a superb commercial transaction. World class management team here . well done

[nimbo10] 18/9/2024 11:23

Sure is mega, feel comfortable now no cap in hand for fundraise, which was a major flag for new investors.

[zen12] 18/9/2024 11:22

RNS out:Transaction to establish Strategic Partnership with leading global endoscopy manufacturer Sale of 51% interest in Creo's European subsidiary for approximately €36.7m in cash on a cash free, debt free basis Access to expanded complementary OEM product portfolio for distribution through Creo's channels

[pacsltd] 18/9/2024 11:17

@peterrr3 why did you say 'well done all holders' ? i.e. what do you mean ?

[peterrr3] 18/9/2024 11:15

Too right Dr B, well done all holders.

[dr biotech] 16/9/2024 21:25

Fwiw Walbrook (Investor relations) said it could be assumed results were “in line”. Not really sure that they would know otherwise though.

[peterrr3] 16/9/2024 19:11

They have until the end of the month. IMO if they were any good they would have provided a trading update first like last year. I see steady progress but not fast enough to get over the cash flow hump, although I hope I am wrong.

[1swifty] 16/9/2024 17:53

Evening everyone. Anyone have update / thoughts on when 2024 H1 results to be published. Trading update was early last year in August, and results were out on 12th September 2023 for that H1.

[peterrr3] 15/9/2024 09:53

Building presence in the US Midwest, trial in Texas now clinical training roles open in Arizona.

[peterrr3] 05/9/2024 17:11

New microwave ablation tool patent applied for, scaled down allowing broader application. Fits existing RF delivery probes and can deliver RF and microwave simultaneously or individually.https://patentscope.wipo.int/search/en/detail.jsf?docId=US437308419&_cid=P10-M0PJ2B-48618-1

[peterrr3] 28/8/2024 10:05

A successful trial in Texas should deliver the required clinical evidence across all parameters, but you are looking at Dec 2025.The unit has a tie in with Mayo, so I am sure they will be looking closely too and hopefully train up a few staff.So given the time line unfortunately I think another placement is more probable than not.

[dr biotech] 28/8/2024 08:39

If you look at the company forecasts they don't factor in a great increase in the Kamaptive partnerships. Even if Intuitive said today they were going to recommend speed boat for POEM and other procedures then the operatives still need training etc. I'm not sure whether CREO could supply other kit that is more "like for like" that doesn't need training (as they sell through their consumables division) but I don't really see that happening.

What they need is great clinical results and the data that proves this kit gives better outcomes, reduces aftercare needs and saves money. Then hopefully the rest will follow.

The company forecasts can be found here

hxxps://www.creomedical.com/assets/uploads/media/2023/12/corporate-presentation-march-2023.pdf

Obviously they still have everything to prove on the sales front. That will be easier to judge with the results and outlook in Sept. FWIW I think even then it will be in the balance

[innnovate] 27/8/2024 17:11

I think it's worth pointing out that Joanne Hart recommended Creo at the time of the listing back in 2016.

It was a good tip and happily I made money on it.

However Creo came down hard from those highs.

Looking back across the 8 years of public listing, the company has not really done it for shareholders, unless you were particularly smart/lucky with timing. I'm awaiting (possibly in vain) another favorable entry point to meaningfully get back into the stock.

We are still to see Creo's tech earn meaningful revenues and 'hoping' (at this point it's no more than that) that those revenues the company can secure in the short-term are enough to prevent it from returning to the market for more cash. For a number of reasons, the path of organic sales growth will be long and is far from certain.

The greater commercial and investor upside lies in one of its 2 robotics partners selecting CREO tech as part of their ecosystem. Such a decision likely within the next couple of years. Patience continues to be needed here.

[dr biotech] 27/8/2024 14:53

I think more engagement can only be a good thing. I think this lot have done OK - they have at least done some Investormeets where your average PI can ask questions and the occasional investor conference. I guess it also takes up management time.

Might be some other innocuous reason - CEO/CFO being on holiday over August etc. I guess we'll see when the results do come out.

[bihas2019] 27/8/2024 14:38

Thanks for following up. New chairman new approach? We should get H1 results by end of September in any case. Personally I'm not a fan of less comms as an approach if that's what the plan is going forward, they set a precedent of a trading update in early August, might have been a better way to manage expectations rather then just not bother this year